Comparison · NCT01167881-8032ca02
Empaglifozin 25 mg vs Glimepiride: The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Empaglifozin 25 mg vs Glimepiride: The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment. Trial comparisons, record NCT01167881-8032ca02. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01167881-8032ca02
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0248 | 0.016 | 0.0385 | wilson | |
| Risk in group 2 | 0.242 | 0.214 | 0.274 | wilson | |
| Risk difference, group 1 minus group 2 | -0.217 | -0.25 | -0.186 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.103 | 0.0646 | 0.163 | log | |
| Odds ratio, group 1 over group 2 | 0.0796 | 0.0491 | 0.129 | log | |
| Number needed to treat, for one fewer participant with the outcome on Empaglifozin 25 mg than on Glimepiride | 4.6 | 4 | 5.39 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Empaglifozin 25 mg | Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.~Empagliflozin: 25 mg once daily~Placebo: Placebo matching Glimepiride | 19 | 765 | OG000 |
| Group 2 | Glimepiride | Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.~Glimepiride: 1-4 mg once daily~Placebo: Placebo matching Empagliflozin | 189 | 780 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.
- Description
- Time frame
- baseline and 104 weeks
- Population
- Treated set, all patients treated with at least one dose of randomised study drug.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
- NCT number
- NCT01167881
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, Glimepiride, Placebo, Placebo
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2014-08-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01167881?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01167881-8032ca02